Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE $^{103}$Pd brachytherapy source

Keith T. Sowards

Department of Radiation Oncology, University of Louisville, James Brown Cancer Center, Louisville, Kentucky
ktsoawa01@louisville.edu

Received 13 October 2006; accepted 5 January 2007

For roughly 25 years, $^{125}$I and $^{103}$Pd sources have been used in the treatment of various malignant diseases such as prostate cancer. Various new sources have been marketed and produced to meet the demand for new sources to use in treatment. Recently, IsoAID LLC created the ADVANTAGE $^{103}$Pd source. Various dosimetric parameters must be determined to facilitate treatment planning using this source. Theoretical determination of dosimetric characteristics, dose rate constant, radial dose function, and anisotropy function for this new source followed the American Association of Physicists in Medicine (AAPM) Task Group 43U recommendations. Theoretical calculations were performed in liquid water using the PTRAN Monte Carlo code version 7.44. The radial dose function of the new source was calculated in liquid water at distances up to 10.0 cm, and the anisotropy function, at distances ranging from 0.5 cm to 7.0 cm. The anisotropy factors and anisotropy constant were derived from the anisotropy function. The results in water indicate that the dose rate constant is $0.709 \pm 0.014 \text{ cGy} \cdot \text{h}^{-1} \cdot \text{U}^{-1}$ and that the anisotropy constant is $0.880 \pm 0.040$. The dosimetric characteristics of this new source compare favorably with those of other commercially available $^{103}$Pd sources.

PACS: 87.53.Jw

Key words: $^{103}$Pd, dosimetry, Monte Carlo, brachytherapy

I. INTRODUCTION

For approximately 25 years, $^{103}$Pd brachytherapy sources have been produced for use in interstitial implants in various tumor sites. Sources using $^{103}$Pd are favored because their low-energy photon emissions provide a rapid decrease in dose with increasing distance, minimizing the dose to normal tissues.

Use of ultrasound-guided brachytherapy seed implantation for prostate cancer has increased greatly since the technique was developed in the early 1980s. The reasons for the increase are many, including patient convenience (one treatment versus many for external-beam radiotherapy), reduced side effects as compared with radical prostatectomy, and greater cost effectiveness.\(^{1-4}\) With a shortage of available seeds and an increase in the number of procedures being performed nationally, several manufacturers, including IsoAid (IsoAid LLC, Port Richey, FL), have developed new $^{103}$Pd sources to meet the increasing demand.
II. MATERIALS AND METHODS

A. Source of $^{103}$Pd

The ADVANTAGE $^{103}$Pd source has a physical length of 4.5 mm and an outer diameter of 0.8 mm. To create the four active 0.5-mm polystyrene spheres, $^{103}$Pd isotope is absorbed throughout the spheres, which are then encapsulated in a 0.05-mm–thick titanium capsule (Fig. 1). A silver rod, 0.5 mm in diameter and 1.25 mm in length, serves as an X-ray marker and is placed between the pair of spheres at each end of the capsule. An active length of 3.4 mm was assumed for this source during calculation of the source parameters.

B. Monte Carlo simulation

Dose distributions for the ADVANTAGE source were calculated in liquid water using the PTRAN Monte Carlo code.\(^{(5-7)}\) Simulations were performed for up to 10 million histories divided into one hundred batches. By combining this number of histories with use of a distance- and attenuation-averaged, bounded, next-flight point-kerma estimator\(^{(5)}\) standard errors about the mean (67% confidence intervals) ranging from 1.5% (near the source: $r < 3$ cm) to 5%–6% (far from the source: $r > 5$ cm) were achieved.

One assumption made in the Monte Carlo simulation of the dose distributions around the source was that a uniform distribution of the $^{103}$Pd isotope is present within each polystyrene sphere. A density of 1.046 g/cm\(^3\) was assumed for each polystyrene sphere. The X-ray marker at the center of the source is 1.25 mm in length and 0.5 mm in diameter. The overall physical length of the source is 4.5 mm, with an outer diameter of 0.8 mm. The internal cavity of the source is filled with dry air. The PTRAN code used the $^{103}$Pd photon spectrum extracted from the Medical Internal Radiation Dosimetry (MIRD) pamphlet 10.\(^{(6)}\)

The Monte Carlo–simulated dose rate constant was obtained by calculating the kerma rate to water at the reference point (1 cm, $\pi/2$) in a medium and then dividing that result by the simulated air kerma ($S_k$) strength of the source. The $S_k$ was determined by calculating the air kerma rate at 10 cm distance and correcting for the inverse square of the distance to obtain the value at 1 cm while suppressing characteristic X-ray production. It is understood, but impractical, to simulate at the distance that the National Institute of Standards and Technology (NIST) uses (100 cm). Such a simulation would have required extremely long run times to yield even marginal uncertainty levels. Using 10 cm as a reference yields good uncertainty at a great enough distance to fairly approximate true NIST calibration standards. In the calculations, simulations in air were performed with the titanium characteristic X-ray production suppressed. The air kerma rate strength per unit contained activity is given in cGy•cm\(^2\)•h\(^{-1}\)•mCi\(^{-1}\).

Fig. 1. Schematic diagram of the ADVANTAGE $^{103}$Pd brachytherapy source (courtesy of IsoAid LLC). The area between the capsule and the X-ray marker is filled with air.
C. Dosimetry technique

Characteristics of the source were determined theoretically according to Task Group Report No. 43 (TG-43(U1)) from the American Association of Physicists in Medicine (AAPM). Under that protocol, the dose distribution around a sealed brachytherapy source can be determined using the formalism

\[
\frac{D(r, \theta)}{S_K} = \Lambda G(r, \theta) g(r) F(r, \theta),
\]

where \(S_K\) is the air kerma strength of the source, \(\Lambda\) is the dose rate constant at a reference point \((r_0, \theta_0)\) or \((1 \text{ cm}, \pi/2)\), \(G(r, \theta)\) is the geometry function, \(g(r)\) is the radial dose function, and \(F(r, \theta)\) is the anisotropy function. The above quantities are thoroughly defined and discussed in great detail in TG-43(U1) and that discussion will therefore not be repeated here.

The goal of the present project was to compare the calculated dosimetric parameters of the IsoAid ADVANTAGE \(^{103}\)Pd brachytherapy source with those of other commercially available \(^{103}\)Pd sources. The determinations were performed according to the methodology outlined in TG-43(U1) and in accordance with the AAPM recommendations for source calibration.

III. RESULTS

The dose rate constant, \(\Lambda\), of the ADVANTAGE \(^{103}\)Pd source was determined using the equation

\[
\Lambda = \frac{D(r, \theta)}{S_K}.
\]

As shown in Table 1, the Monte Carlo calculations yielded a value of 0.709 \(\pm 0.014\) cGy•h\(^{-1}\)•U\(^{-1}\) in liquid water. The uncertainty of the Monte Carlo simulation was determined by combining the uncertainties of the dose rate calculated in medium and the calculated air kerma rate. The air kerma rate was obtained from the Monte Carlo data by simulating the dose rate at 1 cm in phantom and then dividing that result by the simulated dose rate at 10 cm in air with characteristic X-ray production suppressed. The resulting value was then corrected for the effects of the inverse square law.

| Source model       | Reference                  | Method                  | Medium     | Dose rate constant \(\Lambda \text{ (cGy•h}^{-1}\text{•U}^{-1})\) |
|--------------------|----------------------------|-------------------------|------------|----------------------------------------------------------|
| ADVANTAGE \(^{103}\)Pd | Present work               | Monte Carlo simulation | Liquid water | 0.709\(\pm 0.014\) \(^{b}\) |
| ADVANTAGE \(^{103}\)Pd | Meigooni et al. (12)       | Monte Carlo simulation | Liquid water | 0.690\(\pm 0.021\) \(^{b}\) |
|                     |                           | Monte Carlo Simulation  | Solid water | 0.670\(\pm 0.020\) \(^{b}\) |
|                     |                           | Measured, TLD           | Liquid water | 0.680\(\pm 0.020\) |
| Theragenics Model 200 \(^{103}\)Pd | Williamson (13)          | Monte Carlo simulation | Liquid water | 0.680\(\pm 0.020\) |
|                     |                           | TG43U1                  | Liquid water | 0.686\(\pm 0.020\) |
| Best Industries \(^{103}\)Pd | Meigooni et al. (14)   | Monte Carlo simulation | Liquid water | 0.670\(\pm 0.020\) |
|                     |                           | Measured, TLD           | Solid water | 0.690\(\pm 0.055\) |
|                     |                           | TG43U1                  | Liquid water | 0.670\(\pm 0.027\) |
| NAS MED3633 \(^{103}\)Pd | Li et al. (15)            | Monte Carlo simulation | Liquid water | 0.677\(\pm 0.020\) |
|                     |                           | Measured, TLD           | Solid water | 0.680\(\pm 0.041\) |
|                     |                           | TG43U1                  | Liquid water | 0.688\(\pm 0.020\) |

\(^{a}\) 1U = 1 cGy•cm\(^2\)•h\(^{-1}\).

\(^{b}\) Corrected per the TG-43(U1) recommendations of the American Association of Physicists in Medicine.
The radial dose function of the source was calculated in water from 0.1 cm to 10 cm. The uncertainty of the calculated data is ±3%. Fig. 2 shows a comparison between the calculated $g(r)$ of the ADVANTAGE source and a selection of other commercially available sources. Table 2 presents the values of $g(r)$ in water. Those values were obtained by simulating the dose rate at each $g(r)$ distance and then normalizing to the simulated dose rate at 1 cm. The result was then corrected for inverse square relation as per TG-43.

![Graph showing comparison between calculated radial dose functions](image)

**Fig. 2.** Comparison in water of the Monte Carlo–calculated radial dose function of the ADVANTAGE $^{103}$Pd source with radial dose functions of other commercially available sources.

**Table 2.** The calculated radial dose function of the ADVANTAGE $^{103}$Pd brachytherapy source in liquid water

| Distance from source center, $r$ (cm) | Radial dose function, $g(r)$ | Present work |
|-------------------------------------|-----------------------------|--------------|
|                                     | Meigooni et al.$^{12,13}$   | Monte Carlo  |
|                                     | Liquid water                | Measured TLD | Monte Carlo  |
|                                     | Solid water                 | Liquid water |
| 0.1                                 | 0.915                       | 1.000        |
| 0.2                                 | 1.234                       | 0.768        |
| 0.3                                 | 1.296                       | 0.750        |
| 0.4                                 | 1.290                       | 0.586        |
| 0.5                                 | 1.263 1.243 1.289 1.260     | 0.576        |
| 0.6                                 | 1.213                       | 0.429        |
| 0.7                                 | 1.160                       | 0.318        |
| 0.75                                | 1.134                       | 0.233        |
| 0.8                                 | 1.106                       | 0.092        |
| 0.9                                 | 1.053                       | 0.069        |
| 1.0                                 | 1.000 1.000 1.000 1.000     | 0.050        |
| 1.5                                 | 0.761 0.720 0.750 0.768     | 0.037        |
| 2.0                                 | 0.579 0.536 0.555 0.576     | 0.023        |
| 2.5                                 | 0.431                       | 0.028        |
| 3.0                                 | 0.323 0.296 0.292 0.318     | 0.020        |
| 3.5                                 | 0.235 0.211 0.233           | 0.020        |
| 4.0                                 | 0.177 0.157 0.153 0.173     | 0.015        |
| 4.5                                 | 0.127 0.107 0.127           | 0.011        |
| 5.0                                 | 0.092 0.085 0.077 0.092     | 0.008        |
| 5.5                                 |                             | 0.006        |
| 6.0                                 | 0.050 0.048 0.042 0.050     | 0.005        |
| 6.5                                 |                             | 0.037        |
| 7.0                                 | 0.029 0.030 0.023 0.028     | 0.008        |
| 7.5                                 |                             | 0.006        |
| 8.0                                 | 0.018 0.014 0.015           | 0.005        |
| 8.5                                 |                             | 0.011        |
| 9.0                                 |                             | 0.008        |
| 9.5                                 |                             | 0.006        |
| 10.0                                |                             | 0.005        |

Journal of Applied Clinical Medical Physics, Vol. 8, No. 2, Spring 2007
Many treatment planning systems require a polynomial fit to \( g(r) \). For use of this data in those various treatment planning systems, the calculated \( g(r) \) in water in the range of 0.1 cm to 10 cm was fitted to a fifth-order polynomial function defined as follows:

\[
g(r) = a_0 + a_1r + a_2r^2 + a_3r^3 + a_4r^4 + a_5r^5,
\]

where \( a_0 = 1.1983 \), \( a_1 = 7.3502 \times 10^{-2} \), \( a_2 = -3.1789 \times 10^{-1} \), \( a_3 = 9.1913 \times 10^{-2} \), \( a_4 = -9.9569 \times 10^{-3} \), and \( a_5 = 3.7557 \times 10^{-4} \). This fifth-order polynomial fit has been found to fail to accurately reproduce the \( g(r) \) at radial distances greater than 10 cm; however, it is accurate at distances less than 10 cm.

The anisotropy function of the source was calculated in liquid water for distances ranging from 0.5 cm to 7 cm. Those values were obtained by simulating the dose rate at each angle and normalizing to the dose rate at 90 degrees and at the radial distance in question. The result was then corrected using the geometry function relationship as defined in TG-43. The uncertainties of the calculated values range from ±5% to ±6%.

Fig. 3 shows the variation of \( F(r, \theta) \) in water as a function of distance from the source. Figs. 4 and 5 compare the anisotropy function of the ADVANTAGE source with those of several other commercially available sources at 1 cm and 5 cm respectively.

---

**Fig. 3.** Variation of the Monte Carlo–simulated \( F(r, \theta) \) of the ADVANTAGE \(^{103}\)Pd source in liquid water at distances ranging from 0.5 cm to 7 cm.

**Fig. 4.** Comparison in liquid water at 1 cm radius of the Monte Carlo–simulated anisotropy functions of the ADVANTAGE \(^{103}\)Pd source with the anisotropy functions of other commercially available sources.
function of the ADVANTAGE source, the anisotropy factors $\phi_{\text{an}}(r)$ and the anisotropy constant $\overline{\phi}_{\text{an}}$ have been extracted. Table 3 shows the anisotropy functions, anisotropy factors, and anisotropy constant of the ADVANTAGE source in liquid water. Table 4 compares the anisotropy factors and constant with those of other commercially available sources. The calculated anisotropy constant for the ADVANTAGE source in water was $0.880 \pm 0.040$.

![Comparison in liquid water at 5 cm radius of the Monte Carlo–simulated anisotropy function of the ADVANTAGE $^{103}\text{Pd}$ source with the anisotropy functions of other commercially available sources.](image)

**Table 3.** Monte Carlo–simulated two-dimensional anisotropy function of the ADVANTAGE $^{103}$Pd brachytherapy source in liquid water

| Angle $\theta$ (degrees) | $F(r,\theta)$ | $\phi_{\text{an}}(r)$ | $\overline{\phi}_{\text{an}}$ |
|--------------------------|--------------|-------------------------|-----------------------------|
| 0                        | 0.319        | 0.940                   | 0.880 ± 0.040              |
| 5                        | 0.333        | 0.890                   |                             |
| 10                       | 0.349        | 0.860                   |                             |
| 15                       | 0.436        | 0.852                   |                             |
| 20                       | 0.520        | 0.880                   |                             |
| 25                       | 0.807        | 0.902                   |                             |
| 30                       | 0.852        | 0.911                   |                             |
| 35                       | 0.880        | 0.910                   |                             |
| 40                       | 0.902        | 0.899                   |                             |
| 45                       | 0.941        | 0.897                   |                             |
| 50                       | 1.021        | 0.906                   |                             |
| 55                       | 1.020        | 0.906                   |                             |
| 60                       | 1.016        | 0.906                   |                             |
| 65                       | 1.009        | 0.909                   |                             |
| 70                       | 1.003        | 0.909                   |                             |
| 75                       | 0.997        | 0.909                   |                             |
| 80                       | 0.992        | 0.909                   |                             |
| 85                       | 0.990        | 0.909                   |                             |
| 90                       | 1.000        | 0.909                   |                             |
IV. DISCUSSION AND CONCLUSIONS

The dose rate constant of the ADVANTAGE $^{103}$Pd source was found to be $0.709 \pm 0.014$ cGy $\cdot$ h$^{-1}$ $\cdot$ U$^{-1}$. This value is in good agreement with other commercially available $^{103}$Pd sources. Table 1 compares the dose rate constant of the ADVANTAGE source with the dose rate constants calculated for several other commercially available $^{103}$Pd sources such as the Model 200 source by Williamson(13); previous work on the ADVANTAGE source calculated by Meigooni et al.(12); the NAS MED3633 calculated by Li and Palta(15); and the Best $^{103}$Pd calculated by Meigooni et al.(14).

Fig. 2 compares the $g(r)$ for the new source with those for other commercially available sources such as the Model 200 source determined by Williamson(13); previous work on the ADVANTAGE source determined by Meigooni et al.(12); NAS MED3633 determined by Li and Palta(15); and the Best $^{103}$Pd determined by Meigooni et al.(14). The figure shows that the radial dose function of the ADVANTAGE $^{103}$Pd source is in good agreement with those of the other sources.

Fig. 3 shows the variation of the anisotropy function with radial distance in water. The $F(r, \theta)$ of the ADVANTAGE source in water was compared with those of the Model 200 source determined by Weaver(16); previous work on the ADVANTAGE source determined by Meigooni et al.(12); the NAS MED3633 determined by Li and Palta(15); and the Best $^{103}$Pd determined by Meigooni et al.(14) (Figs. 4 and 5). The figures show good agreement between the ADVANTAGE source and other $^{103}$Pd sources for angular ranges of 20 degrees to 90 degrees. Below 20 degrees, differences in endcap construction yield significant deviations in the plotted anisotropy functions.

Table 3 presents the values of the measured and calculated anisotropy functions, anisotropy factors, and anisotropy constants for the ADVANTAGE source in liquid water. Table 4 compares the anisotropy factors and constant of the ADVANTAGE source with other commercially available $^{103}$Pd sources. The anisotropy constant of the ADVANTAGE $^{103}$Pd source in water was found to be $0.880 \pm 0.040$.

The dosimetric characteristics of the ADVANTAGE source were theoretically determined based on TG-43(U1) recommendations. These characteristics were found to be comparable to the values reported for other commercially available $^{103}$Pd sources. As per TG-43(U1), the parameters determined in liquid water are recommended for clinical applications.

ACKNOWLEDGMENT

This project was supported by IsoAid LLC. Special thanks are due to Ali Meigooni for his assistance in the preparation of this manuscript.
REFERENCES

1. Wallner K, Merrick G, True L, Cavanaugh W, Simpson C, Butler W. $^{125}$I versus $^{103}$Pd for low-risk prostate cancer: modality outcomes from a prospective randomized multicenter trial. Cancer J. 2002;8(1):67–73.
2. Dattoli M, Wallner K, True L, Cash J, Sorace R. Long term outcomes after treatment with external beam radiation therapy and $^{103}$Pd for patients with higher risk prostate carcinoma. Cancer J. 2003;9(4):979–983.
3. Porrazzo MS, Hilaris BS, Moorthy CR, et al. Permanent interstitial implantation using $^{103}$Palladium: The New York Medical College preliminary experience. Int J Radiat Oncol Biol Phys. 1992;23(5):1033–1036.
4. Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based control following ultrasound guided $^{125}$I implantation for stage T1/T2 prostate carcinoma. J Urol. 1995;154(3):1096–1099.
5. Williamson JF. Monte Carlo evaluation of kerma at a point for photon transport problems. Med Phys. 1987;14(4):567–576.
6. Dillman LT, Van der Lage FC. Radionuclide Decay Schemes and Nuclear Parameters for Use in Radiation-Dose Estimates. NM/MIRD pamphlet No. 10. Revised edition. New York (NY): Society of Nuclear Medicine, Medical Internal Radiation Dose Committee; 1975.
7. Williamson JF. Monte Carlo simulation of photon transport phenomena. In: Morin RL, editor. Monte Carlo Simulation in the Radiological Sciences. Boca Raton (FL): CRC Press; 1988: 53–102.
8. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22(2):209–234.
9. Meigooni AS, Williamson JF, Nath R. Single source dosimetry for interstitial brachytherapy. In: Williamson JF, Thomadson BR, Nath R, editors. Brachytherapy Physics. Madison (WI): Medical Physics Publishing Corporation; 1995: 210–233.
10. Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):633–674. [Erratum in: Med Phys. 2004;31(12):3532–3533]
11. Williamson JF, Coursey BM, DeWerd LA, Hanson WF, Nath R, Ibott GS. Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Med Phys. 1998;25(12):2269–2270.
12. Meigooni AS, Dini SA, Dou K, Awan SB, Gopalakrishnan G. Experimental and Monte Carlo dosimetric characterization of ADVANTAGE $^{103}$Pd. Appl Radiat Isot. 2006;64(8):881–887.
13. Williamson JF. Monte Carlo modeling of the transverse-axis dose distribution of the model 200 $^{103}$Pd interstitial brachytherapy source. Med Phys. 2000;27(4):643–654.
14. Meigooni AS, Bharucha Z, Yoe–Sein M, Sowards K. Dosimetric characteristics of the Best double-wall $^{103}$Pd brachytherapy source. Med Phys. 2001;28(12):2568–2575.
15. Li Z, Palta JR, Fan JJ. Monte Carlo calculations and experimental measurements of dosimetry parameters of a new $^{103}$Pd source. Med Phys. 2000;27(5):1108–1112.
16. Weaver KA. Anisotropy functions for $^{125}$I and $^{103}$Pd sources. Med Phys. 1998;25(12):2271–2278.